Victory Capital Management Inc. Acquires 4,272 Shares of Henry Schein, Inc. (NASDAQ:HSIC)

Posted by on May 27th, 2023

Victory Capital Management Inc. raised its holdings in Henry Schein, Inc. (NASDAQ:HSIC – Get Rating) by 7.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 61,758 shares of the company’s stock after acquiring an additional 4,272 shares during the period. Victory Capital Management Inc.’s holdings in Henry Schein were worth $5,320,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of HSIC. UBS Group AG boosted its stake in shares of Henry Schein by 48.8% during the third quarter. UBS Group AG now owns 155,032 shares of the company’s stock valued at $10,197,000 after purchasing an additional 50,840 shares in the last quarter. IFP Advisors Inc lifted its stake in shares of Henry Schein by 8.7% in the fourth quarter. IFP Advisors Inc now owns 2,698 shares of the company’s stock worth $389,000 after acquiring an additional 217 shares during the period. Fox Run Management L.L.C. acquired a new position in shares of Henry Schein in the fourth quarter worth approximately $539,000. Boston Trust Walden Corp lifted its stake in shares of Henry Schein by 1.9% in the fourth quarter. Boston Trust Walden Corp now owns 556,241 shares of the company’s stock worth $44,427,000 after acquiring an additional 10,188 shares during the period. Finally, Prudential PLC lifted its stake in shares of Henry Schein by 604.9% in the third quarter. Prudential PLC now owns 27,019 shares of the company’s stock worth $1,777,000 after acquiring an additional 23,186 shares during the period. Institutional investors own 95.45% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts recently commented on the company. StockNews.com lowered Henry Schein from a “buy” rating to a “hold” rating in a research note on Thursday, May 11th. Barrington Research dropped their price target on Henry Schein from $92.00 to $90.00 in a research note on Wednesday, May 10th. Morgan Stanley dropped their price target on Henry Schein from $70.00 to $69.00 and set an “underweight” rating on the stock in a research note on Tuesday, February 21st. UBS Group boosted their price target on Henry Schein from $75.00 to $82.00 and gave the company a “neutral” rating in a research note on Tuesday, March 7th. Finally, Credit Suisse Group dropped their price target on Henry Schein from $99.00 to $97.00 and set an “outperform” rating on the stock in a research note on Tuesday, February 28th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and three have assigned a buy rating to the company. According to MarketBeat, Henry Schein has an average rating of “Hold” and an average price target of $85.67.

Insiders Place Their Bets

In other Henry Schein news, EVP Mark E. Mlotek sold 24,747 shares of the stock in a transaction that occurred on Friday, May 19th. The stock was sold at an average price of $76.68, for a total value of $1,897,599.96. Following the completion of the sale, the executive vice president now owns 69,138 shares in the company, valued at approximately $5,301,501.84. The transaction was disclosed in a document filed with the SEC, which is available at this link. In related news, COO Michael S. Ettinger sold 14,881 shares of the firm’s stock in a transaction that occurred on Wednesday, May 24th. The stock was sold at an average price of $75.12, for a total transaction of $1,117,860.72. Following the completion of the transaction, the chief operating officer now owns 75,710 shares of the company’s stock, valued at approximately $5,687,335.20. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Mark E. Mlotek sold 24,747 shares of the firm’s stock in a transaction that occurred on Friday, May 19th. The shares were sold at an average price of $76.68, for a total value of $1,897,599.96. Following the transaction, the executive vice president now directly owns 69,138 shares of the company’s stock, valued at approximately $5,301,501.84. The disclosure for this sale can be found here. In the last 90 days, insiders sold 47,942 shares of company stock worth $3,667,662. 1.14% of the stock is currently owned by company insiders.

Henry Schein Price Performance

Shares of Henry Schein stock opened at $74.92 on Friday. The company has a current ratio of 1.82, a quick ratio of 0.94 and a debt-to-equity ratio of 0.25. The firm has a market capitalization of $9.81 billion, a PE ratio of 21.41, a price-to-earnings-growth ratio of 2.12 and a beta of 0.82. The business’s 50-day moving average price is $80.18 and its 200-day moving average price is $80.83. Henry Schein, Inc. has a 12 month low of $64.75 and a 12 month high of $89.72.

Henry Schein (NASDAQ:HSIC – Get Rating) last announced its quarterly earnings data on Tuesday, May 9th. The company reported $1.21 EPS for the quarter, missing the consensus estimate of $1.23 by ($0.02). Henry Schein had a net margin of 3.82% and a return on equity of 15.41%. The firm had revenue of $3.06 billion for the quarter, compared to the consensus estimate of $3.09 billion. During the same quarter last year, the company posted $1.30 earnings per share. Henry Schein’s revenue for the quarter was down 3.7% compared to the same quarter last year. Sell-side analysts forecast that Henry Schein, Inc. will post 5.26 EPS for the current fiscal year.

Henry Schein Profile

(Get Rating)

Henry Schein, Inc engages in the provision of health care products and services to medical, dental, and veterinary office-based practitioners. It operates through the Healthcare Distribution and Technology and Value-Added Services segments. The Healthcare Distribution segment includes consumable products, laboratory, small and large equipment repair services, branded and generic pharmaceuticals, vaccines, surgical, diagnostic tests, infection-control products, and vitamins.

Featured Stories

Institutional Ownership by Quarter for Henry Schein (NASDAQ:HSIC)

Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.